Answers are grounded in this paper and cite their sources.
Background Vitamin B12, folate and thyroid-function testing are routinely included in dementia workups, but their prognostic significance after a neurocognitive-disorder diagnosis remains uncertain. Methods We analyzed a deidentified Taiwanese tertiary-hospital cohort of patients aged ≥65 years with neurocognitive disorders (dementia or mild cognitive impairment; n = 7,969). The prespecified primary analyses were mixed-effects models of annual MMSE and CDR-SB trajectories in which baseline vitamin B12, folate, TSH and free thyroxine were entered jointly, restricted to patients with all four biomarkers and at least two assessments (MMSE n = 818; CDR-SB n = 1,009). CDR progression and all-cause mortality were secondary outcomes, and prescription-record analyses were exploratory. Sensitivity analyses addressed missing data, selection into the analysis sets, competing risks, confounding, laboratory timing and prior treatment. Results Biomarker testing and repeated cognitive assessment were clinically driven, so all estimates apply to a selected tested-and-followed subgroup that was younger, less impaired and less likely to die than untested or unfollowed patients. Higher baseline vitamin B12 was associated with slower MMSE decline (β +0.146 points/year per SD, 95% CI +0.038 to +0.255; FDR q = 0.017), an association retained after multiple imputation and selection weighting but attenuated after excluding patients treated before baseline. The full-range association of higher TSH with slower decline on both scales was not robust: it depended on a few patients with TSH > 10 mIU/L and was absent within the euthyroid range. Folate deficiency was associated with faster CDR progression (HR 1.57, 95% CI 1.13–2.19, p = 0.008), including in competing-risk models; the estimate for vitamin B12 deficiency was imprecise (HR 1.22, 95% CI 0.88–1.69, p = 0.23) and does not exclude a clinically relevant increase. Higher vitamin B12 was associated with all-cause mortality (HR 1.035 per 100 pg/mL, 95% CI 1.016–1.055), but this was attenuated after flexible adjustment for renal function. Documented vitamin B12 supplementation showed no detectable association with CDR-SB trajectory in a small exploratory matched analysis. Conclusion In patients who underwent biomarker testing and repeated cognitive assessment, routine biomarkers from workups for reversible causes provided modest, context-dependent prognostic information. We interpret these associations as possible indicators of clinical state rather than evidence that the biomarkers, or their correction, influence the progression of neurocognitive disorders.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: